WHO ICTRP trial
PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study…
EUCTR2016-004744-11-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2016-004744-11-NL |
|---|---|
| Public title | PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT) |
| Scientific title | PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT) - PERFECT |
| Primary sponsor | Academic Medical Center |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | oesophageal cancer;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: tecentriq Product Name: Tecentriq Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: ATEZOLIZUMAB CAS Number: 1380723-44-3 Other descriptive name: Tecentriq Concentration unit: mg… |
| Registration date | Feb 27, 2017 |
| Secondary IDs | PERFECT |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: